ALKS Alkermes plc

Alkermes plc (NASDAQ:ALKS) reported on September 21 that adults receiving the investigational oral drug ALKS 7290 showed improved symptoms of attention-deficit hyperactivity disorder (ADHD). After 14 days, median reductions on the Adult ADHD Investigator Symptom Rating Scale were 14 points at a total daily dose of 20 mg and 19 points at 50 mg. Both […]

Alkermes plc on Monday released topline results Monday from its Phase 1 proof-of-concept study evaluating ALKS 7290, an investigational orexin 2 receptor agonist designed to treat attention-deficit hyperactivity disorder (ADHD) in adults. The trial provided the first clinical evidence of...

In September 2026, Alkermes plc reported positive topline results from a phase 1b proof-of-concept study of ALKS 7290, an investigational orexin 2 receptor agonist, which showed clinically meaningful, dose-dependent improvements in adult ADHD symptoms over 14 days with a generally well-tolerated safety profile. These data represent the first clinical evidence of an orexin receptor agonist’s effects in ADHD, potentially widening Alkermes’ orexin franchise beyond sleep disorders and other...

Alkermes (ALKS) recent attention-deficit/hyperactivity disorder data increased its management's conf

ALKS posts positive Phase I data for ALKS 7290, showing meaningful improvements in ADHD symptoms across dose levels in healthy volunteers and adults.

Alkermes’ results heightened anticipation for a coming readout in 2027. Elsewhere, AbbVie leaned into AI drug discovery and the FDA expanded use of Eli Lilly’s breast cancer pill.

Alkermes stock jumped Monday on the first proof-of-concept for its orexin-modulating drug in adults with ADHD.

Alkermes plc (NASDAQ:ALKS) shares gained 6. 5% on Monday after the company reported positive Phase 1b clinical trial results for ALKS 7290, an investigational treatment for adults with attention-deficit hyperactivity disorder (ADHD).

The insider still has significant holdings in the company, signaling confidence.

Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

INDV's proposed Supernus merger could broaden its CNS portfolio, cut costs and reduce reliance on Sublocade, but closing remains uncertain.

Indivior's Sublocade growth and cost cuts are lifting earnings and cash flow, but pipeline setbacks, legal risks and valuation add caution.

Alkermes gains 26.5% in three months as strong proprietary product sales and pipeline progress fuel momentum into the rest of 2026.

It was reported on July 28 that Alkermes plc (NASDAQ:ALKS) sank 5% to $50.05 following its second-quarter 2026 financial report. Despite topping top-line consensus estimates with a 27% year-over-year revenue surge to $496.0 million, profit-taking took hold after a massive year-to-date rally. The second-quarter revenue growth was anchored by $411.7 million in proprietary net sales. […]

The FDA approved the first drug to treat a root cause of narcolepsy, which could help other sleep conditions as well.

Alkermes stock has delivered a strong 84.5% return over the past year, yet its broader valuation checks suggest the shares are not a straightforward bargain at current levels. The 84.5% one-year gain puts recent performance front and center, which naturally raises the question of how much optimism is already in the share price. Expectations around Alkermes' orexin pipeline can support higher earnings potential, while any setback in development or commercialization may weigh heavily on what...

Alkermes (NasdaqGS:ALKS) shares were in focus after the company reported its second quarter 2026 results on July 28, highlighting higher revenue alongside a significantly lower quarterly net income figure. See our latest analysis for Alkermes. Despite the weaker quarterly net income, Alkermes shares trade at US$48.99 after a recent pullback, with the 7 day share price return down 7.37% and the 30 day share price return down 5.28%. However, the 90 day share price return of 46.76% and 1 year...

Alkermes' (ALKS) base business supported the company's Q2 beat, while its orexin pipeline serves as

Moby summary of Alkermes plc's Q2 2026 earnings call

Alkermes PLC (ALKS) reports significant sales growth and strategic advancements, while navigating potential market competition and profitability hurdles.